Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

Hospitals win on $2.4B raise, AO reports, 90-day meaningful use in final IPPS rule

CMS has finalized the Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) payment rules, lowering the total increase to $2.4 billion while removing a controversial proposal to require public release of previously confidential hospital inspections by accrediting organizations (AOs).

Children's National Health System welcomes Marva Moxey-Mims, M.D., renowned nephrologist, as incoming Division Chief

Marva Moxey-Mims, M.D., a leading expert in chronic kidney disease and glomerular disease who has conceptualized and overseen multicenter clinical studies aimed at improving chronic kidney disease treatment, has been named Chief of Pediatric Nephrology at Children's National Health System.

Brigham and Women’s may ask more employees to take voluntary buyouts

Boston’s Brigham and Women’s Hospital may ask more of its 18,000 employees to voluntarily give up their jobs to minimize forced layoffs.

Thumbnail

Expensive exams benefiting medical boards

Nonprofit medical boards reported a $23 million surplus in 2013, more than triple what was recorded a decade earlier. Most of that revenue comes from charging physicians for certification exams.

Practicing on 3D-printed models cuts surgery time, costs

Practicing before a surgery, especially for procedures on children, helps reduce surgery time and costs. In a study published in the Journal of Children's Orthopaedics, engineers and pediatric orthopedic surgeons have utilized 3D printing to help surgeons train for a common hip disorder in children 9 to 16 that cuts surgery times by 25 percent.

Lobbyist groups takes credit for malpractice bill passed by House

The Physician Insurers Association of America (PIAA), a group which lobbies for medical liability insurance companies, is claiming a bill passed by the House to limit malpractice damages was largely written by the group, not members of Congress.

Court ruling may stop Trump from cutting off ACA insurer subsidies

The U.S. Court of Appeals for the District of Columbia Circuit has allowed 16 state attorneys general to intervene in a lawsuit surrounding the Affordable Care Act’s cost-sharing reduction subsidies, or CSRs, paid to insurers for lowering deductibles for low-income ACA enrollees.

HIMSS Launches Steve Lieber Innovator Scholarship

The Steve Lieber Innovator Scholarship, sponsored by the HIMSS Foundation, recognizes the leadership and passion for innovation in digital health technology of its namesake, HIMSS president and CEO for more than 17 years.

Displaying 4377 - 4384 of 6649

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup